Drug Database
Back to search

Poland· PL-100456612

Darifenacin Aristo

A darifenacin product containing darifenacinum, registered in Poland by Aristo Pharma Sp. z o.o.. The same ATC class is registered in 15 of our 19 countries.

ATC G04BD10

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedDarifenacin AristoATCG04BD10REGISTER NO.PL-100456612PACKS LISTED4CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about darifenacinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Darifenacin is registered in 15 of 19 countries.

Countries holding a registration under ATC G04BD10 (darifenacin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search darifenacin products by name

Darifenacin · ATC G04BD10

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of darifenacin costs, country by country.

Normalised to the WHO defined daily dose (7.5 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Darifenacin · price per daily dose (7.5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$1.84
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Darifenacinum
Manufacturer
Aristo Pharma Sp. z o.o.
Country
Poland (PL)
ATC code
G04BD10
ATC class
Darifenacin
Defined daily dose
7.5 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 4

  • gtin
    05909991493349
  • gtin
    05909991493356
  • gtin
    05909991493363
  • gtin
    05909991493370

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

246 interactions on record for darifenacin.

Graded by severity as the source publishes them — 13 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check darifenacin against other medicinesHow interaction checks work

Darifenacin · interactions on record

246 records

  • 13 severe
  • 155 moderate
  • 1 minor
  • 49 info

Most severe, free to view

  • Potassium chlorideA12BA01severe
  • Potassium citrateA12BA02severe
  • EliglustatA16AX10severe
  • Potassium chlorideB05XA01severe

28 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Darifenacin in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All darifenacin products

Authorised across Europe · EMA

The same active substance is authorised in 8 EEA countries. Names it is sold under:

  • Germany · Darifenacin Aristo
  • Spain · Darifenacina Aristo
  • United Kingdom (Northern Ireland) · Darifenacin Aristo
  • Iceland · Emselex
  • Liechtenstein · Emselex
  • Netherlands · Darifenacine Aristo
  • Norway · Emselex
  • Portugal · Darifenacina Aristo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ac667aa5-7f2a-498e-be18-a2fa2cbafe38
GET /v1/drugs/ac667aa5-7f2a-498e-be18-a2fa2cbafe38?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki o przedłużonym uwalnianiu",
  "source": "urpl",
  "strength": "7,5 mg",
  "packaging": "05909991493349 ¦ Rp ¦ 146394\n14 tabl.\n05909991493356 ¦ Rp ¦ 146395\n28 tabl.\n05909991493363 ¦ Rp ¦ 146396\n49 tabl.\n05909991493370 ¦ Rp ¦ 146397\n98 tabl.",
  "substance": "Darifenacini hydrobromidum 8.923 mg",
  "common_name": "Darifenacinum",
  "pl_product_id": "100456612",
  "pozwolenie_nr": "27333",
  "auth_procedure": "MRP",
  "authorisation_validity": "2023-12-06"
}
API referenceMCP serverPlans

See everything about darifenacin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console